<DOC>
	<DOCNO>NCT03082209</DOCNO>
	<brief_summary>This open-label , Phase I , dose-escalation study determine determine maximum tolerate dose ( MTD ) and/or recommend phase two dose ( RPTD ) , evaluate safety , efficacy , pharmacokinetic ( PK ) profile ABBV-621 participant previously treat solid tumor hematologic malignancy . The study consist 2 segment : Segment I ( Dose Escalation ) Segment II ( Dose Expansion ) .</brief_summary>
	<brief_title>A Study Safety Tolerability ABBV-621 Participants With Previously Treated Solid Tumors Hematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Must diagnosis solid tumor , AML nonHodgkin lymphoma ( NHL ) relapse , progress , fail respond least one systemic therapy . Must measurable disease , define RECIST 1.1 , compute tomography ( CT ) magnetic resonance imaging ( MRI ) , except AML , must histologically confirm relapsed refractory disease local institution . Must Eastern Cooperative Oncology Group ( ECOG ) Performance Score 0 2 . Must adequate hematologic , renal hepatic function . Participants history brain metastasis show clinical radiographic stable disease least 28 day definitive therapy . Receipt systemic anticancer agent , include investigational anticancer product , within 21 day prior study drug administration 5 halflives , whichever longer . Participant history cirrhosis indication significant hepatic function compromise . Participant positive diagnosis hepatitis A , B , C .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>non-Hodgkin lymphoma</keyword>
	<keyword>Solid Tumors</keyword>
	<keyword>acute myeloid leukemia ( AML )</keyword>
	<keyword>Cancer</keyword>
	<keyword>Hematologic Malignancies</keyword>
	<keyword>colorectal cancer ( CRC )</keyword>
</DOC>